Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 1/2010

01-06-2010 | Clinical Case

A Case of Dystrophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis

Authors: Dr Emanuela Gubinelli, Corrado Angelo, Valeria Pacifico

Published in: American Journal of Clinical Dermatology | Special Issue 1/2010

Login to get access

Abstract

Epidermolysis bullosa is a group of inherited, chronic, non-inflammatory skin disorders, and dystrophic epidermolysis bullosa (DEB) is one of the most severe variants. The role of tumour necrosis factor alpha (TNFα) has not been reported in the pathogenesis of DEB. A DEB case is reported that appears to have responded well to the TNFα inhibitor etanercept given for the treatment of concomitant psoriatic arthritis. A progressive improvement in DEB was apparent over the first 3 months of treatment and persistent good control of DEB was noted over 3 years of therapy. A correlation between DEB improvement and etanercept has not been made, but the case may provide insight into the causal mechanisms of DEB.
Literature
1.
Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009; 60: 203–11PubMedCrossRef
2.
Chopra V, Tyring SK, Johnson L, et al. Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production. J Clin Immunol 1990; 10: 321–9PubMedCrossRef
3.
Chopra V, Tyring SK, Johnson L, et al. Peripheral blood mononuclear cell subsets in patients with severe inherited forms of epidermolysis bullosa. Arch Dermatol 1992; 128: 201–9PubMedCrossRef
Metadata
Title
A Case of Dystrophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis
Authors
Dr Emanuela Gubinelli
Corrado Angelo
Valeria Pacifico
Publication date
01-06-2010
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue Special Issue 1/2010
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/1153427-S0-000000000-00000

Other articles of this Special Issue 1/2010

American Journal of Clinical Dermatology 1/2010 Go to the issue

Review Article

Psoriatic Arthritis: A Dermatologist’s Perspective

Review Article

Adverse Effects of Biological Agents in the Treatment of Psoriasis

Review Article

Psoriasis: Targeting Therapy Towards the Inflammatory Cascade

Review Article

Managing Pediatric Patients with Psoriasis

Review Article

Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis

Clinical Case

Etanercept Therapy for Psoriasis in a Patient with Numerous Comorbidities